XML 28 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Our disaggregated revenues were as follows (in thousands):
Year Ended December 31,
202220212020
Royalties$360,475 $203,900 $88,596 
Product sales, net
  Sales of bulk rHuPH2082,084 80,960 38,956 
Sale of proprietary products72,849 23,264 17,031 
Sale of Device Partnered Products36,097 — — 
Total product sales, net$191,030 $104,224 $55,987 
Revenues under collaborative agreements:
  Upfront license and target nomination fees30,000 42,000 37,264 
  Event-based development milestones and regulatory milestone and other fees59,000 42,000 69,500 
  Sales-based milestones10,000 50,000 15,000 
  Device Licensing and development revenue9,611 1,186 1,247 
Total revenues under collaborative agreements$108,611 $135,186 $123,011 
Total revenue$660,116 $443,310 $267,594 
During the year ended December 31, 2022 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $429.5 million. This amount represents royalties and sales milestone earned in the current period, as well as $59.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. We also recognized revenue of $2.0 million during the year ended December 31, 2022 that had been included in deferred revenues at December 31, 2021. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.
Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):
December 31, 2022December 31, 2021
Accounts receivable, net$186,970 $90,975 
Other contract assets$44,102 $— 
Deferred revenues$5,499 $4,276 
As of December 31, 2022, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $80.7 million of which $75.2 million relates to unfulfilled product purchase orders and $5.5 million has been collected and reported as deferred revenues. The unfulfilled product purchase orders are estimated to be delivered in 2023. Of the total deferred revenues of $5.5 million, $3.2 million is expected to be used by our customers within the next 12 months.
We recognized contract assets of $44.1 million as of December 31, 2022, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.